MenB Behind 97% of Meningococcal Cases in 15 to 24s, UKHSA Says

What the new UKHSA figures show

On 10 September 2026 the UK Health Security Agency (UKHSA) published figures showing Meningitis B (MenB) caused 97% of invasive meningococcal disease (IMD) cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. The data cover a full year in which meningococcal infection remained a serious concern for teenagers and young adults, and they place MenB firmly at the centre of the picture for this age group. England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths. The figures also show that MenB was the leading cause across almost all age groups under 25: infants 92% (34 of 37) and 1 to 4 year olds 100% (35 of 35).

Dr Shamez Ladhani, UKHSA Consultant Epidemiologist, said today's figures show how real the risk is and that two doses are essential. The publication arrives as a one off, time limited NHS MenB vaccination programme, launched in summer 2026, seeks to reach those at highest immediate risk, primarily school leavers and first year university and higher education undergraduates. The NHS had given 246,089 MenB doses to young people as of 31 August 2026, but thousands of eligible school leavers and first years had not yet come forward. UKHSA says two doses are essential for the best protection and urges eligible students to get both, ideally before term starts.

Why first-year students face a higher risk

First year university students face a risk of meningococcal disease around 7 times higher than young people of the same age who do not go to university. The reasons are well established in public health surveillance: freshers mix closely with large numbers of new people, often in crowded social settings, and many carry the bacteria without becoming ill. Meningococcal bacteria live in the back of the nose and throat and spread through close contact, so the start of term creates conditions in which infection can pass between students quickly. For parents, the practical implication is that the weeks around freshers' week 2026 are a period of heightened risk for a group that may not have been eligible for MenB vaccination in childhood.

The UKHSA figures underline why this age group is a priority. MenB caused 97% of IMD cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. That concentration of cases in a narrow age band is the basis for the current vaccination push. The NHS programme is time limited and aimed at those at highest immediate risk, primarily school leavers and first year university and higher education undergraduates. Students and parents can check eligibility and book through the NHS 'Book a MenB vaccination appointment' service. UKHSA urges eligible students to get both doses, ideally before term starts.

The 2026 outbreaks in Kent, Dorset and Berkshire

In March 2026 an outbreak in Kent was associated with 21 cases in students and young people in the Canterbury area, followed by outbreaks of 3 or more cases in Dorset and Berkshire. The outbreaks caused 3 deaths and some survivors face life long health consequences. The Kent outbreak was the largest of the three and prompted a rapid public health response, including vaccination for close contacts and wider communication with students and universities in the area. The subsequent outbreaks in Dorset and Berkshire showed that the risk was not confined to a single campus or region, and they reinforced the case for a national approach to protecting school leavers and first year students.

England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths. The outbreaks in Kent, Dorset and Berkshire accounted for a small but significant share of cases and for 3 of the deaths. Meningococcal disease can progress quickly, and survivors may face life long health consequences including hearing loss, limb loss, brain injury and scarring. The UKHSA figures published on 10 September 2026 show MenB caused 97% of IMD cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. The outbreaks and the national data together explain why the NHS launched a one off, time limited MenB vaccination programme in summer 2026.

The time-limited NHS MenB programme: who is eligible and how to book

A one off, time limited NHS MenB vaccination programme was launched in summer 2026 for those at highest immediate risk, primarily school leavers and first year university and higher education undergraduates. The programme is designed to close a protection gap: MenB vaccination was not part of the routine childhood schedule for this cohort when they were younger, so many teenagers and young adults have not been vaccinated against MenB. The NHS had given 246,089 MenB doses to young people as of 31 August 2026, but thousands of eligible school leavers and first years had not yet come forward. Booking and eligibility checks are via the NHS 'Book a MenB vaccination appointment' service.

UKHSA says two doses are essential for the best protection and urges eligible students to get both, ideally before term starts. Students who have not yet booked should check their eligibility and arrange an appointment as soon as possible, and parents can help by reminding school leavers and first years to do the same. The programme is time limited, so those who delay may miss the opportunity to be vaccinated under these arrangements. Vinny Smith, Meningitis Research Foundation chief executive, said the programme is a critical step towards closing the protection gap for teenagers and young adults. Dr Tom Nutt, Meningitis Now chief executive, said students cannot afford to underestimate the risk.

Why two doses matter

UKHSA says two doses are essential for the best protection and urges eligible students to get both, ideally before term starts. A single dose may provide some protection, but the second dose is needed to achieve the best immune response and to extend protection through the period of highest risk, which for first year students includes the first weeks and months of university life. The NHS had given 246,089 MenB doses to young people as of 31 August 2026, and the programme continues to offer appointments to eligible school leavers and first year undergraduates. Students who have had one dose should ensure they receive the second dose at the recommended interval.

Dr Shamez Ladhani, UKHSA Consultant Epidemiologist, said today's figures show how real the risk is and that two doses are essential. The call for two doses is particularly important in the context of the 2026 outbreaks in Kent, Dorset and Berkshire, which caused 3 deaths and left some survivors facing life long health consequences. England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths, and MenB caused 97% of IMD cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. Completing the two dose course is the best way for eligible students to reduce their risk, according to UKHSA.

Symptoms to watch for in yourself and friends

The vaccine does not protect against all infections that cause meningitis and septicaemia. Symptoms can occur in any order and include high temperature, cold hands and feet, vomiting, confusion, fast breathing, muscle and joint pain, pale or mottled skin, a rash (harder to see on brown or black skin), headache, stiff neck, dislike of bright lights, drowsiness and seizures. Seek medical advice straight away. Students should be aware that early symptoms can resemble a hangover or flu, and that the rash may not appear at all or may be difficult to see on darker skin. Friends and flatmates are often the first to notice that someone is seriously unwell.

Parents and students should treat any combination of these symptoms as a potential emergency and contact NHS 111 or emergency services without delay. The UKHSA figures published on 10 September 2026 show MenB caused 97% of IMD cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths. The 2026 outbreaks in Kent, Dorset and Berkshire caused 3 deaths and some survivors face life long health consequences. Rapid recognition and treatment save lives, and vaccination remains the best available protection for eligible students.

MenACWY and routine infant vaccines

MenACWY vaccine covers meningococcal A, C, W and Y; all teenagers remain eligible until their 25th birthday. The MenACWY vaccine does not protect against MenB, and the MenB vaccine does not protect against A, C, W or Y, so eligible students should ensure they are up to date with both where offered. The current NHS MenB programme is separate from the routine MenACWY teenage offer, and students who have missed MenACWY can still ask about it. Parents are reminded infants should receive all 3 routine MenB doses on time. The UKHSA figures show MenB was the leading cause across almost all age groups under 25: infants 92% (34 of 37) and 1 to 4 year olds 100% (35 of 35).

England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths. The data published on 10 September 2026 show MenB caused 97% of IMD cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. For families with children at different stages, the message is twofold: infants should receive all 3 routine MenB doses on time, and teenagers and first year students should take up the vaccines for which they are eligible, including MenACWY until their 25th birthday and the time limited MenB programme for school leavers and first year undergraduates. Booking and eligibility checks for MenB are via the NHS 'Book a MenB vaccination appointment' service.

Related coverage on Kael Tripton: Student Money in the First Term: Bank Accounts, Overdrafts, Rent, Guarantors and Budgeting, Student Finance Dates: When to Apply, What Evidence You Need and When the Money Arrives, Results Day: Student Finance if Your University Changes, MenB Vaccine 2026: What Freshers Need to Know Before University, Private medical insurance and NHS waiting times: what the waiting list data says and what PMI does and does not cover.

Frequently asked questions

What did the UKHSA figures published on 10 September 2026 show?

The UK Health Security Agency published figures showing Meningitis B (MenB) caused 97% of invasive meningococcal disease (IMD) cases in 15 to 24 year olds in England in 2025 to 2026: 93 of 96 cases. England recorded 348 confirmed IMD cases in 2025 to 2026, with 26 deaths. MenB was also the leading cause across almost all age groups under 25: infants 92% (34 of 37) and 1 to 4 year olds 100% (35 of 35).

Why are first year university students at higher risk?

First year university students face a risk of meningococcal disease around 7 times higher than young people of the same age who do not go to university. Close mixing with large numbers of new people, often in crowded social settings, allows meningococcal bacteria to spread more easily. Many students carry the bacteria without becoming ill. The start of term and freshers' week are therefore a period of heightened risk, which is why the NHS MenB programme prioritises school leavers and first year undergraduates.

Who is eligible for the NHS MenB vaccination programme in 2026?

A one off, time limited NHS MenB vaccination programme was launched in summer 2026 for those at highest immediate risk, primarily school leavers and first year university and higher education undergraduates. Booking and eligibility checks are via the NHS 'Book a MenB vaccination appointment' service. The NHS had given 246,089 MenB doses to young people as of 31 August 2026, but thousands of eligible school leavers and first years had not yet come forward. UKHSA urges eligible students to get both doses, ideally before term starts.

Why are two doses of the MenB vaccine needed?

UKHSA says two doses are essential for the best protection and urges eligible students to get both, ideally before term starts. The second dose is needed to achieve the best immune response and to extend protection through the period of highest risk. Dr Shamez Ladhani, UKHSA Consultant Epidemiologist, said today's figures show how real the risk is and that two doses are essential. Students who have had one dose should ensure they receive the second at the recommended interval.

What symptoms should students and parents watch for?

The vaccine does not protect against all infections that cause meningitis and septicaemia. Symptoms can occur in any order and include high temperature, cold hands and feet, vomiting, confusion, fast breathing, muscle and joint pain, pale or mottled skin, a rash (harder to see on brown or black skin), headache, stiff neck, dislike of bright lights, drowsiness and seizures. Seek medical advice straight away. Early symptoms can resemble flu or a hangover, and the rash may not appear or may be difficult to see on darker skin.